Tagged with R&D

France The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership in the past few years, her perspective on market access in France and the challenges and opportunities she has faced…

pharma The CEO and founder of ModiQuest discusses how, with its unique, fully-integrated antibody generation and development platform, the company is developing antibodies for potentially groundbreaking therapies for the prevention and treatment of rheumatoid arthritis and growing its already well-established CRO arm serving clients from around the world. Could you introduce…

pharma The general manager of Ferring South Africa, Mercia Van Zyl discusses the company’s ambitious plans for the future under the slogan ‘People come first’, the placement of fertility under the nation’s therapeutic priorities, and how the company is contributing to an overall better healthcare system in the country. Could you…

pharma The CEO of BioConnection, the leading contract services and manufacturing organization for the development and production of injectable (bio)pharmaceutical products, explains how —thanks to flexibility and quality-driven mentality —the company helps small and medium biotech companies and universities make their products reality. This year BioConnection celebrates its tenth anniversary and…

pharma The Netherlands provides a flourishing environment for biotech to grow. The vice president for European operations at Kite Pharma discusses how biotech start-ups can find their path to success and how Kite Pharma is looking at new innovative therapies for cancer treatment. Before joining T-Cell Factory, later acquired by Kite…

pharma Hans Schikan offers insights into the flourishing Dutch life sciences sector and the attractiveness of the local eco-system, citing a combination of the right science and the right attitude of people as the key formula for success. In 2014/2015, three Dutch biotechs (UniQure, ProQR, Galapagos) went public on Nasdaq, and…

pharma Lygature is the new name of TI Pharma and CTMM, two internationally renowned public-private-partnerships turned non-for-profit partnership drivers. Managing Director Jorg Janssen explains that it will be business as usual for the merged organization, but with more opportunities for cross-disciplinary collaborations than ever before. Lygature drives partnerships for the development of…

Pharma The Director of the newly formed Necker Institute for Sick Children reveals how the inspiration behind INEM was to bring people together in order to create a common scientific policy and campus spirit and why collaboration between clinicians and researchers is crucial in a, which is heavily reliant on scientific…

pharma The Centre for Human Drug Research provides a full range of early stage clinical pharmacology services. The CEO discusses the vision behind the creation of the foundation as well as some of its most recent educational and funding initiatives destined to help biotech companies develop new drugs. You founded the…

pharma  Pfizer Global Established Products’ BU Head and  Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well as the challenges faced by the French biosimilars market and what Pfizer-Hospira is doing to achieve the huge potential in…

Pharma The general manager of Drogsan, Ersan Kuçuk elaborates on the company’s efforts in shifting towards more value-added pharmaceutical products, specifically within the realm of biosimilars, while highlighting his ambitions in expanding the company’s presence within OTC. He also illustrates the decision to move Drogsan’s R&D department to the Gazi University…

Pharma Over the past few years BMS has consolidated its footprint in Puerto Rico to transform the island into a manufacturing hub for both biopharma and pharmaceuticals. The plant manager of the oral solid Humacao plant discusses the current challenges the site is facing as well as the company’s future development…